Group B Streptococcal Peptide Mimetic Vaccine

Information

  • Research Project
  • 6444827
  • ApplicationId
    6444827
  • Core Project Number
    R43AI051086
  • Full Project Number
    1R43AI051086-01
  • Serial Number
    51086
  • FOA Number
  • Sub Project Id
  • Project Start Date
    5/15/2002 - 22 years ago
  • Project End Date
    4/30/2004 - 20 years ago
  • Program Officer Name
    RUBIN, FRAN A.
  • Budget Start Date
    5/15/2002 - 22 years ago
  • Budget End Date
    4/30/2003 - 21 years ago
  • Fiscal Year
    2002
  • Support Year
    1
  • Suffix
  • Award Notice Date
    5/3/2002 - 22 years ago

Group B Streptococcal Peptide Mimetic Vaccine

Group B streptococcus (GBS) causes invasive infections of newborns, pregnant women and adults with underlying medical conditions, such as diabetes or cancer. Despite antibiotic treatment, estimated case fatality rates of 5-20% in neonates and 15-32% in adults establish the prevention of GBS infections as a public health priority. Peptide immunogens that mimic the structure of GBS capsular polysacharide (CPS) antigens would provide an alternate vaccine strategy, compared to currently tested CPS-conjugates for induction of maternal antibodies to prevent neonatal infection. The long-term goal of the proposed research is to develop a multi-valent peptide mimotope vaccine for prevention of GBS infections caused by the predominant serotypes Ia, Ib, II, III, and V. The proposed work is a direct extension of research identifying peptides that mimic type III CPS. Phase I use anti-CPS antibodies to select phage libraries to identify peptides that bind uniquely to the antibodies; and to determine whether the selected peptides are true mimotopes of the CPS. Phase II innovative vaccine approaches utilizing peptide mimotopes of microbial polysaccharides offer the design and development of T-dependent immune responses and better immunologic memory for prevention of disease. PROPOSED COMMERCIAL APPLICATIONS: A successful GBS vaccine incorporated into prenatal care would the most cost-effective prevention of GBS infection in newborns. The vaccine would have a large market potential among child-bearing women and possibly adults with underlying medical conditions. In addition, the generation of serotype-specific monoclonal antibody reagents and serotype-specific peptide mimetics could be marked as diagnostic and epidemiological research tools. The proposed 3D pulse sequence family will e made available for MRI scanners of all major MR hardware manufacturers equipped with high- performance gradient systems, it will help 3D MRI to become a major diagnostic tool in modern radiology and in-vivo imaging research in general by overcoming many of the obstacles, such as the long acquisition time, that are holding back current 3D MRI techniques.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R43
  • Administering IC
    AI
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    299937
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    856
  • Ed Inst. Type
  • Funding ICs
    NIAID:299937\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    LIGOCYTE PHARMACEUTICALS, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    BOZEMAN
  • Organization State
    MT
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    597186831
  • Organization District
    UNITED STATES